Cost-effectiveness analysis of the introduction of rotavirus vaccine in Iran
Abstract Background Although the mortality from diarrheal diseases has been decreasing dramatically in Iran, it still represents an important proportion of disease burden in children
Gespeichert in:
| Veröffentlicht in: | Vaccine 2015-05, Vol.33, p.A192-A200 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | A200 |
|---|---|
| container_issue | |
| container_start_page | A192 |
| container_title | Vaccine |
| container_volume | 33 |
| creator | Javanbakht, Mehdi Moradi-Lakeh, Maziar Yaghoubi, Mohsen Esteghamati, Abdoulreza Mansour Ghanaie, Roxana Mahmoudi, Sussan Shamshiri, Ahmad-Reza Zahraei, Seyed Mohsen Baxter, Louise Shakerian, Sareh Chaudhri, Irtaza Fleming, Jessica A Munier, Aline Baradaran, Hamid R |
| description | Abstract Background Although the mortality from diarrheal diseases has been decreasing dramatically in Iran, it still represents an important proportion of disease burden in children |
| doi_str_mv | 10.1016/j.vaccine.2014.12.035 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1717493580</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X14016880</els_id><sourcerecordid>1717493580</sourcerecordid><originalsourceid>FETCH-LOGICAL-c528t-f015b397aef416ae7eaef9409ee08875416a4ac1dbb36bed9d9482f60328e3e63</originalsourceid><addsrcrecordid>eNqFkk2LFDEQhoMo7rj6E5QGL166TeWjO7koMvixMOBBBW8hna7GjD3JmnQPzL837YwKe9lTQvHUm8r7FiHPgTZAoX29b47WOR-wYRREA6yhXD4gG1Adr5kE9ZBsKGtFLYB-vyJPct5TSiUH_ZhcMalBQ0s3ZLeNea5xHNHN_ogBc65ssNMp-1zFsZp_YOXDnOKwFCCGtZbibI8-Lbm6jFCI6ibZ8JQ8Gu2U8dnlvCbfPrz_uv1U7z5_vNm-29VOMjXXIwXZc91ZHAW0FjssNy2oRqRKdXItCutg6Hve9jjoQQvFxpZyppBjy6_Jq7PubYq_FsyzOfjscJpswLhkAx10QnOp6P1o23VKccF4QV_eQfdxScWLP5QomlLJQskz5VLMOeFobpM_2HQyQM2ajNmbiy1mTcYAMyWZ0vfior70Bxz-df2NogBvzwAW544ek8nOY3A4-FTCMUP09z7x5o6Cm3zwzk4_8YT5_29MLg3my7oe63aAKJqqmPUbe461_w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1674717585</pqid></control><display><type>article</type><title>Cost-effectiveness analysis of the introduction of rotavirus vaccine in Iran</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>ProQuest Central UK/Ireland</source><creator>Javanbakht, Mehdi ; Moradi-Lakeh, Maziar ; Yaghoubi, Mohsen ; Esteghamati, Abdoulreza ; Mansour Ghanaie, Roxana ; Mahmoudi, Sussan ; Shamshiri, Ahmad-Reza ; Zahraei, Seyed Mohsen ; Baxter, Louise ; Shakerian, Sareh ; Chaudhri, Irtaza ; Fleming, Jessica A ; Munier, Aline ; Baradaran, Hamid R</creator><creatorcontrib>Javanbakht, Mehdi ; Moradi-Lakeh, Maziar ; Yaghoubi, Mohsen ; Esteghamati, Abdoulreza ; Mansour Ghanaie, Roxana ; Mahmoudi, Sussan ; Shamshiri, Ahmad-Reza ; Zahraei, Seyed Mohsen ; Baxter, Louise ; Shakerian, Sareh ; Chaudhri, Irtaza ; Fleming, Jessica A ; Munier, Aline ; Baradaran, Hamid R</creatorcontrib><description>Abstract Background Although the mortality from diarrheal diseases has been decreasing dramatically in Iran, it still represents an important proportion of disease burden in children <5 years old. Rotavirus vaccines are among the most effective strategies against diarrheal diseases in specific epidemiological conditions. This study aimed to evaluate the cost-effectiveness of the introduction of rotavirus vaccine (3 doses of pentavalent RotaTeq® (RV5)) in Iran, from the viewpoints of Iran's health system and society. Methods The TRIVAC decision support model was used to calculate total incremental costs, life years (LYs) gained, and disability-adjusted life years (DALYs) averted due to the vaccination program. Necessary input data were collected from the most valid accessible sources as well as a systematic review and meta-analysis on epidemiological studies. We used WHO guidelines to estimate vaccination cost. An annual discount rate of 3% was considered for both health gain and costs. A deterministic sensitivity analysis was performed for testing the robustness of the models results. Results Our results indicated that total DALYs potentially lost due to rotavirus diarrhea within 10 years would be 138,161, of which 76,591 could be prevented by rotavirus vaccine. The total vaccination cost for 10 cohorts was estimated to be US$ 499.91 million. Also, US$ 470.61 million would be saved because of preventing outpatient visits and inpatient admissions (cost-saving from the society perspective). We estimated a cost per DALY averted of US$ 2868 for RV5 vaccination, which corresponds to a highly cost-effective strategy from the government perspective. In the sensitivity analysis, all scenarios tested were still cost-saving or highly cost-effective from the society perspective, except in the least favorable scenario and low vaccine efficacy and disease incidence scenario. Conclusion Based on the findings, introduction of rotavirus vaccine is a highly cost-effective strategy from the government perspective. Introducing the vaccine to the national immunization program is an efficient use of available funds to reduce child mortality and morbidity in Iran.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2014.12.035</identifier><identifier>PMID: 25919160</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Allergy and Immunology ; Child, Preschool ; Cost-Benefit Analysis ; Cost-effectiveness ; DALY ; Diarrhea ; Diarrhea - economics ; Diarrhea - epidemiology ; Diarrhea - prevention & control ; Health Policy ; Humans ; Immunization ; Immunization Programs ; Infant ; Infant, Newborn ; Iran ; Iran - epidemiology ; Models, Statistical ; Mortality ; Rotavirus ; Rotavirus diarrhea ; Rotavirus Infections - economics ; Rotavirus Infections - epidemiology ; Rotavirus Infections - prevention & control ; Rotavirus Vaccines - administration & dosage ; Rotavirus Vaccines - economics ; Rotavirus Vaccines - immunology ; Sensitivity analysis ; Studies ; TRIVAC model ; Vaccination - economics ; Vaccination - methods ; Vaccine ; Vaccines ; Vaccines, Attenuated - administration & dosage ; Vaccines, Attenuated - economics ; Vaccines, Attenuated - immunology</subject><ispartof>Vaccine, 2015-05, Vol.33, p.A192-A200</ispartof><rights>Elsevier Ltd</rights><rights>2014 Elsevier Ltd</rights><rights>Copyright © 2014 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited May 7, 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c528t-f015b397aef416ae7eaef9409ee08875416a4ac1dbb36bed9d9482f60328e3e63</citedby><cites>FETCH-LOGICAL-c528t-f015b397aef416ae7eaef9409ee08875416a4ac1dbb36bed9d9482f60328e3e63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1674717585?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,64361,64363,64365,65309,72215</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25919160$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Javanbakht, Mehdi</creatorcontrib><creatorcontrib>Moradi-Lakeh, Maziar</creatorcontrib><creatorcontrib>Yaghoubi, Mohsen</creatorcontrib><creatorcontrib>Esteghamati, Abdoulreza</creatorcontrib><creatorcontrib>Mansour Ghanaie, Roxana</creatorcontrib><creatorcontrib>Mahmoudi, Sussan</creatorcontrib><creatorcontrib>Shamshiri, Ahmad-Reza</creatorcontrib><creatorcontrib>Zahraei, Seyed Mohsen</creatorcontrib><creatorcontrib>Baxter, Louise</creatorcontrib><creatorcontrib>Shakerian, Sareh</creatorcontrib><creatorcontrib>Chaudhri, Irtaza</creatorcontrib><creatorcontrib>Fleming, Jessica A</creatorcontrib><creatorcontrib>Munier, Aline</creatorcontrib><creatorcontrib>Baradaran, Hamid R</creatorcontrib><title>Cost-effectiveness analysis of the introduction of rotavirus vaccine in Iran</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Abstract Background Although the mortality from diarrheal diseases has been decreasing dramatically in Iran, it still represents an important proportion of disease burden in children <5 years old. Rotavirus vaccines are among the most effective strategies against diarrheal diseases in specific epidemiological conditions. This study aimed to evaluate the cost-effectiveness of the introduction of rotavirus vaccine (3 doses of pentavalent RotaTeq® (RV5)) in Iran, from the viewpoints of Iran's health system and society. Methods The TRIVAC decision support model was used to calculate total incremental costs, life years (LYs) gained, and disability-adjusted life years (DALYs) averted due to the vaccination program. Necessary input data were collected from the most valid accessible sources as well as a systematic review and meta-analysis on epidemiological studies. We used WHO guidelines to estimate vaccination cost. An annual discount rate of 3% was considered for both health gain and costs. A deterministic sensitivity analysis was performed for testing the robustness of the models results. Results Our results indicated that total DALYs potentially lost due to rotavirus diarrhea within 10 years would be 138,161, of which 76,591 could be prevented by rotavirus vaccine. The total vaccination cost for 10 cohorts was estimated to be US$ 499.91 million. Also, US$ 470.61 million would be saved because of preventing outpatient visits and inpatient admissions (cost-saving from the society perspective). We estimated a cost per DALY averted of US$ 2868 for RV5 vaccination, which corresponds to a highly cost-effective strategy from the government perspective. In the sensitivity analysis, all scenarios tested were still cost-saving or highly cost-effective from the society perspective, except in the least favorable scenario and low vaccine efficacy and disease incidence scenario. Conclusion Based on the findings, introduction of rotavirus vaccine is a highly cost-effective strategy from the government perspective. Introducing the vaccine to the national immunization program is an efficient use of available funds to reduce child mortality and morbidity in Iran.</description><subject>Allergy and Immunology</subject><subject>Child, Preschool</subject><subject>Cost-Benefit Analysis</subject><subject>Cost-effectiveness</subject><subject>DALY</subject><subject>Diarrhea</subject><subject>Diarrhea - economics</subject><subject>Diarrhea - epidemiology</subject><subject>Diarrhea - prevention & control</subject><subject>Health Policy</subject><subject>Humans</subject><subject>Immunization</subject><subject>Immunization Programs</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Iran</subject><subject>Iran - epidemiology</subject><subject>Models, Statistical</subject><subject>Mortality</subject><subject>Rotavirus</subject><subject>Rotavirus diarrhea</subject><subject>Rotavirus Infections - economics</subject><subject>Rotavirus Infections - epidemiology</subject><subject>Rotavirus Infections - prevention & control</subject><subject>Rotavirus Vaccines - administration & dosage</subject><subject>Rotavirus Vaccines - economics</subject><subject>Rotavirus Vaccines - immunology</subject><subject>Sensitivity analysis</subject><subject>Studies</subject><subject>TRIVAC model</subject><subject>Vaccination - economics</subject><subject>Vaccination - methods</subject><subject>Vaccine</subject><subject>Vaccines</subject><subject>Vaccines, Attenuated - administration & dosage</subject><subject>Vaccines, Attenuated - economics</subject><subject>Vaccines, Attenuated - immunology</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkk2LFDEQhoMo7rj6E5QGL166TeWjO7koMvixMOBBBW8hna7GjD3JmnQPzL837YwKe9lTQvHUm8r7FiHPgTZAoX29b47WOR-wYRREA6yhXD4gG1Adr5kE9ZBsKGtFLYB-vyJPct5TSiUH_ZhcMalBQ0s3ZLeNea5xHNHN_ogBc65ssNMp-1zFsZp_YOXDnOKwFCCGtZbibI8-Lbm6jFCI6ibZ8JQ8Gu2U8dnlvCbfPrz_uv1U7z5_vNm-29VOMjXXIwXZc91ZHAW0FjssNy2oRqRKdXItCutg6Hve9jjoQQvFxpZyppBjy6_Jq7PubYq_FsyzOfjscJpswLhkAx10QnOp6P1o23VKccF4QV_eQfdxScWLP5QomlLJQskz5VLMOeFobpM_2HQyQM2ajNmbiy1mTcYAMyWZ0vfior70Bxz-df2NogBvzwAW544ek8nOY3A4-FTCMUP09z7x5o6Cm3zwzk4_8YT5_29MLg3my7oe63aAKJqqmPUbe461_w</recordid><startdate>20150507</startdate><enddate>20150507</enddate><creator>Javanbakht, Mehdi</creator><creator>Moradi-Lakeh, Maziar</creator><creator>Yaghoubi, Mohsen</creator><creator>Esteghamati, Abdoulreza</creator><creator>Mansour Ghanaie, Roxana</creator><creator>Mahmoudi, Sussan</creator><creator>Shamshiri, Ahmad-Reza</creator><creator>Zahraei, Seyed Mohsen</creator><creator>Baxter, Louise</creator><creator>Shakerian, Sareh</creator><creator>Chaudhri, Irtaza</creator><creator>Fleming, Jessica A</creator><creator>Munier, Aline</creator><creator>Baradaran, Hamid R</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20150507</creationdate><title>Cost-effectiveness analysis of the introduction of rotavirus vaccine in Iran</title><author>Javanbakht, Mehdi ; Moradi-Lakeh, Maziar ; Yaghoubi, Mohsen ; Esteghamati, Abdoulreza ; Mansour Ghanaie, Roxana ; Mahmoudi, Sussan ; Shamshiri, Ahmad-Reza ; Zahraei, Seyed Mohsen ; Baxter, Louise ; Shakerian, Sareh ; Chaudhri, Irtaza ; Fleming, Jessica A ; Munier, Aline ; Baradaran, Hamid R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c528t-f015b397aef416ae7eaef9409ee08875416a4ac1dbb36bed9d9482f60328e3e63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Allergy and Immunology</topic><topic>Child, Preschool</topic><topic>Cost-Benefit Analysis</topic><topic>Cost-effectiveness</topic><topic>DALY</topic><topic>Diarrhea</topic><topic>Diarrhea - economics</topic><topic>Diarrhea - epidemiology</topic><topic>Diarrhea - prevention & control</topic><topic>Health Policy</topic><topic>Humans</topic><topic>Immunization</topic><topic>Immunization Programs</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Iran</topic><topic>Iran - epidemiology</topic><topic>Models, Statistical</topic><topic>Mortality</topic><topic>Rotavirus</topic><topic>Rotavirus diarrhea</topic><topic>Rotavirus Infections - economics</topic><topic>Rotavirus Infections - epidemiology</topic><topic>Rotavirus Infections - prevention & control</topic><topic>Rotavirus Vaccines - administration & dosage</topic><topic>Rotavirus Vaccines - economics</topic><topic>Rotavirus Vaccines - immunology</topic><topic>Sensitivity analysis</topic><topic>Studies</topic><topic>TRIVAC model</topic><topic>Vaccination - economics</topic><topic>Vaccination - methods</topic><topic>Vaccine</topic><topic>Vaccines</topic><topic>Vaccines, Attenuated - administration & dosage</topic><topic>Vaccines, Attenuated - economics</topic><topic>Vaccines, Attenuated - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Javanbakht, Mehdi</creatorcontrib><creatorcontrib>Moradi-Lakeh, Maziar</creatorcontrib><creatorcontrib>Yaghoubi, Mohsen</creatorcontrib><creatorcontrib>Esteghamati, Abdoulreza</creatorcontrib><creatorcontrib>Mansour Ghanaie, Roxana</creatorcontrib><creatorcontrib>Mahmoudi, Sussan</creatorcontrib><creatorcontrib>Shamshiri, Ahmad-Reza</creatorcontrib><creatorcontrib>Zahraei, Seyed Mohsen</creatorcontrib><creatorcontrib>Baxter, Louise</creatorcontrib><creatorcontrib>Shakerian, Sareh</creatorcontrib><creatorcontrib>Chaudhri, Irtaza</creatorcontrib><creatorcontrib>Fleming, Jessica A</creatorcontrib><creatorcontrib>Munier, Aline</creatorcontrib><creatorcontrib>Baradaran, Hamid R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Javanbakht, Mehdi</au><au>Moradi-Lakeh, Maziar</au><au>Yaghoubi, Mohsen</au><au>Esteghamati, Abdoulreza</au><au>Mansour Ghanaie, Roxana</au><au>Mahmoudi, Sussan</au><au>Shamshiri, Ahmad-Reza</au><au>Zahraei, Seyed Mohsen</au><au>Baxter, Louise</au><au>Shakerian, Sareh</au><au>Chaudhri, Irtaza</au><au>Fleming, Jessica A</au><au>Munier, Aline</au><au>Baradaran, Hamid R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cost-effectiveness analysis of the introduction of rotavirus vaccine in Iran</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2015-05-07</date><risdate>2015</risdate><volume>33</volume><spage>A192</spage><epage>A200</epage><pages>A192-A200</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>Abstract Background Although the mortality from diarrheal diseases has been decreasing dramatically in Iran, it still represents an important proportion of disease burden in children <5 years old. Rotavirus vaccines are among the most effective strategies against diarrheal diseases in specific epidemiological conditions. This study aimed to evaluate the cost-effectiveness of the introduction of rotavirus vaccine (3 doses of pentavalent RotaTeq® (RV5)) in Iran, from the viewpoints of Iran's health system and society. Methods The TRIVAC decision support model was used to calculate total incremental costs, life years (LYs) gained, and disability-adjusted life years (DALYs) averted due to the vaccination program. Necessary input data were collected from the most valid accessible sources as well as a systematic review and meta-analysis on epidemiological studies. We used WHO guidelines to estimate vaccination cost. An annual discount rate of 3% was considered for both health gain and costs. A deterministic sensitivity analysis was performed for testing the robustness of the models results. Results Our results indicated that total DALYs potentially lost due to rotavirus diarrhea within 10 years would be 138,161, of which 76,591 could be prevented by rotavirus vaccine. The total vaccination cost for 10 cohorts was estimated to be US$ 499.91 million. Also, US$ 470.61 million would be saved because of preventing outpatient visits and inpatient admissions (cost-saving from the society perspective). We estimated a cost per DALY averted of US$ 2868 for RV5 vaccination, which corresponds to a highly cost-effective strategy from the government perspective. In the sensitivity analysis, all scenarios tested were still cost-saving or highly cost-effective from the society perspective, except in the least favorable scenario and low vaccine efficacy and disease incidence scenario. Conclusion Based on the findings, introduction of rotavirus vaccine is a highly cost-effective strategy from the government perspective. Introducing the vaccine to the national immunization program is an efficient use of available funds to reduce child mortality and morbidity in Iran.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>25919160</pmid><doi>10.1016/j.vaccine.2014.12.035</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2015-05, Vol.33, p.A192-A200 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1717493580 |
| source | MEDLINE; Elsevier ScienceDirect Journals; ProQuest Central UK/Ireland |
| subjects | Allergy and Immunology Child, Preschool Cost-Benefit Analysis Cost-effectiveness DALY Diarrhea Diarrhea - economics Diarrhea - epidemiology Diarrhea - prevention & control Health Policy Humans Immunization Immunization Programs Infant Infant, Newborn Iran Iran - epidemiology Models, Statistical Mortality Rotavirus Rotavirus diarrhea Rotavirus Infections - economics Rotavirus Infections - epidemiology Rotavirus Infections - prevention & control Rotavirus Vaccines - administration & dosage Rotavirus Vaccines - economics Rotavirus Vaccines - immunology Sensitivity analysis Studies TRIVAC model Vaccination - economics Vaccination - methods Vaccine Vaccines Vaccines, Attenuated - administration & dosage Vaccines, Attenuated - economics Vaccines, Attenuated - immunology |
| title | Cost-effectiveness analysis of the introduction of rotavirus vaccine in Iran |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T14%3A19%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cost-effectiveness%20analysis%20of%20the%20introduction%20of%20rotavirus%20vaccine%20in%20Iran&rft.jtitle=Vaccine&rft.au=Javanbakht,%20Mehdi&rft.date=2015-05-07&rft.volume=33&rft.spage=A192&rft.epage=A200&rft.pages=A192-A200&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2014.12.035&rft_dat=%3Cproquest_cross%3E1717493580%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1674717585&rft_id=info:pmid/25919160&rft_els_id=S0264410X14016880&rfr_iscdi=true |